This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


reputable news agency


Peripheral blood haplo-SCT feasible for leukemia patients 70 years and older

Peripheral blood haplo-SCT feasible for leukemia patients 70 years and older

For patients with acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS) aged 70 years and older, haploidentical stem cell transplantation (Haplo-SCT) using a nonmyeloablative conditioning regimen (NMAC) is feasible, with no early nonrelapse mortality (NRM), according to a study published online Nov. 3 in Bone Marrow Transplantation.

Samia Harbi, M.D., from the Institut Paoli-Calmettes in Marseille, France, and colleagues reported a single-center experience of peripheral blood Haplo-SCT with NMAC and posttransplantation cyclophosphamide in 50 patients aged 70 years and older with AML and MDS (27 and 23, respectively). Twenty-four percent of the patients had active disease at Haplo-SCT.

The researchers found that the cumulative incidence was 6 and 25 percent for grade 3 to 4 acute and moderate-to-severe chronic graft-versus-host disease (GVHD), respectively. At day +100, NRM was 0 percent. At three years, NRM, relapse, , and overall survival were 16, 18, 66, and 69 percent, respectively. Eighty-eight percent of patients who were disease-free at two years after Haplo-SCT were living without immunosuppressive treatment.

"We conclude that in highly selected patients ≥70 years, NMAC Haplo-SCT with peripheral blood stem cell and posttransplantation cyclophosphamide is very well tolerated and allowed long-term survival in AML or MDS without persistent chronic GVHD," the authors write.

More information: Samia Harbi et al, Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome, Bone Marrow Transplantation (2023). DOI: 10.1038/s41409-023-02134-w

Copyright © 2023 HealthDay. All rights reserved.

Citation: Peripheral blood haplo-SCT feasible for leukemia patients 70 years and older (2023, December 20) retrieved 25 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Sitagliptin promising addition for preventing acute GVHD


Feedback to editors